Key Highlights
- 8.29% is the intraday gain to USD 4.70 for Strata Critical Medical (NASDAQ:SRTA) per published market data (October 16, 2026 intraday). The gap was +4.84% and the move from the open was +3.30%, on 509,179 shares, 0.8x the average volume.
- USD 72.5 million was Strata's Q2 2026 revenue against USD 45.1 million a year earlier, a rise of 60.8% (own arithmetic), per a summary of the quarterly report. Net loss was USD 10.5 million, or USD 0.12 per share, and adjusted EBITDA margin was 10.9%.
- USD 5.58 was the close after the Q2 report in early August 2026, per the same summary. At USD 4.70 the stock is 15.8% lower (own arithmetic), despite management raising full-year revenue and adjusted EBITDA guidance.
- USD 416 million is the published market capitalisation at USD 4.70, or 1.4x annualised Q2 revenue of USD 290 million (own arithmetic). Three acquisitions in Q2 2026 added perfusion and organ recovery capacity, and free cash flow was a positive USD 2.9 million.
Price Action and Catalyst Review
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026, although the table labels the session as News. Published market data show USD 4.70, up 8.29% from an implied prior close of USD 4.34 (own arithmetic). The gap of +4.84% put the open at USD 4.55, and a further 3.30% gain from the open followed. The advance therefore began at the opening print and extended through the session, which indicates buyers absorbing offers at higher prices rather than an opening move that faded.
Liquidity and Trading Activity
Volume of 509,179 shares at USD 4.70 equals USD 2.39 million of turnover (own arithmetic), or 0.58% of the USD 416 million market capitalisation. Relative volume of 0.8x implies an average of 636,474 shares (own arithmetic), so the label of unusual volume is not supported by the figures: the session ranks below average. An RSI of 43.5 and a technical label of Down per published market data show the stock was recovering from weakness rather than extended after a rally.
Operating Drivers and Risks
Per the quarterly summary, clinical revenue was USD 24.3 million at a 26.1% gross margin, and logistics gross margin was 18.4%, below the 20% long-term target. Management forecast a high single-digit sequential decline in Q3 logistics revenue because one nonexclusive customer is reducing flying. Acquisitions included Ohio Valley Perfusion Associates (May 5), Louisville Perfusion Services (June 2) and a heart and lung recovery program (June 24). Risks are integration cost, the USD 10.5 million quarterly loss, customer concentration and an undisclosed cash balance in the material reviewed.
Where Things Stand
The 8.29% gain is not explained by any filing or release reviewed through October 16, 2026, and the 0.8x relative volume means it was not driven by unusual participation. Strata Critical Medical (NASDAQ:SRTA) still trades 15.8% below its post-earnings close of USD 5.58, so the move recovers part of that decline rather than reversing it. Evidence is balanced: revenue grew 60.8%, free cash flow was positive for a second quarter and guidance was raised, while net losses continue and Q3 logistics revenue is guided lower. The next dated catalyst is the Q3 2026 report, the date of which is not confirmed in the material reviewed.






Please wait processing your request...